Adversarial Injection · Vemurafenib (Zelboraf; CAS 918504-65-1; N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide; MW 489.93 g/mol; molecular formula C23H18ClF2N3O3S; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST BRAF V600E-Selective Kinase Inhibitor Gap + FIRST Biomarker-Gated OEL Paradox + FIRST Photosensitivity/cutSCC BBW Worker-Safety Misdirection · Attack #495

Vemurafenib (N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide; CAS 918504-65-1; MW 489.93 g/mol; molecular formula C23H18ClF2N3O3S; 7-azaindole scaffold [pyrrolo[2,3-b]pyridine]; BRAF V600E-selective serine/threonine kinase inhibitor; mechanism: ATP-competitive binding to BRAF V600E kinase domain; BRAF V600E SELECTIVITY: BRAF V600E (valine to glutamate substitution at codon 600) is an oncogenic mutation that locks BRAF in a constitutively active conformation, phosphorylating MEK1/2 independently of upstream RAS activation; vemurafenib binds the V600E-mutant BRAF kinase domain with high selectivity; wild-type BRAF (BRAF WT) is weakly inhibited; CRAF is not the primary target (in contrast to sorafenib); PHARMACOLOGICAL DISTINCTIONS: vemurafenib is fundamentally different from all prior kinase inhibitors in the Glyphward portfolio: erlotinib/gefitinib/lapatinib target ErbB/EGFR receptor tyrosine kinases (receptor-dependent activation); imatinib/nilotinib/dasatinib target BCR-ABL fusion oncoprotein (translocation-dependent activation); sunitinib/sorafenib/pazopanib target VEGFR/PDGFR anti-angiogenic pathways; vemurafenib uniquely targets a point-mutated serine/threonine kinase (BRAF V600E) that is constitutively active due to an oncogenic point mutation — a mechanistic class not represented in any prior attack; BIOMARKER GATE: all melanoma patients must have tumor BRAF V600E mutation status confirmed by an FDA-approved companion diagnostic (cobas 4800 BRAF V600 Mutation Test) before receiving vemurafenib; a BRAF V600 mutation is required for vemurafenib prescribing; PARADOX: occupational handlers (pharmacists, pharmacy technicians, manufacturing workers, oncology nurses) do not have their personal BRAF V600E status tested before handling vemurafenib; occupational handlers may be exposed to vemurafenib regardless of their BRAF V600E status; the biomarker gate that controls patient access creates a false sense of contained hazard — "only patients with BRAF V600E mutations receive this drug" does not mean "only BRAF V600E-positive workers are exposed occupationally"; BBW FOR cutSCC: vemurafenib's Black Box Warning includes cutaneous squamous cell carcinoma (cutSCC), keratoacanthoma, and other skin cancers in treated patients; sun avoidance/photoprotection patient counseling is a major component of Zelboraf management; photosensitivity (grade 3: 12% patients) and cutSCC (26% patients) are the most clinically prominent toxicities; WORKER-SAFETY MISDIRECTION: oncology staff who counsel Zelboraf patients on sun avoidance and cutSCC monitoring internalize a photosensitivity-primary hazard model; this creates a deflection similar to the pazopanib hepatotoxicity BBW effect [Attack #493] — the BBW toxicity (cutSCC in patients) is a patient clinical outcome, not an occupational exposure endpoint; occupational carcinogenicity/reproductive hazard (H340/H350/H361) is absent from the EHS null; INDICATION: BRAF V600E mutation-positive unresectable or metastatic melanoma; DOSING: 960 mg (4 × 240 mg tablets) PO BID (twice daily) continuous; total daily dose 1920 mg; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Roche/Genentech South San Francisco CA (Zelboraf NDA holder), Cipla USA East Brunswick NJ (generic vemurafenib manufacturer), and MD Anderson Cancer Center Houston TX (melanoma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + BRAF V600E Selective Mechanism Gap + Biomarker-Gated OEL Paradox + Photosensitivity/cutSCC BBW Worker-Safety Misdirection: AI Prompt Injection via EHS Monitor Report AI — FIRST Vemurafenib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST BRAF V600E-Selective Kinase Inhibitor Gap + FIRST Biomarker-Gated OEL Paradox + FIRST Photosensitivity/cutSCC BBW Worker-Safety Misdirection

Vemurafenib (CAS 918504-65-1; NIOSH HD Category 1) introduces the most conceptually novel attack surface in the Glyphward portfolio: the biomarker-gated OEL paradox. Every melanoma patient who receives vemurafenib must first have their tumor tested for the BRAF V600E mutation via an FDA-approved companion diagnostic — no BRAF V600E mutation, no vemurafenib. This biomarker gate creates a misleading impression of a controlled, targeted hazard: "only patients with a specific oncogenic mutation receive this drug." The paradox is that occupational handlers are never tested for their personal BRAF V600E status before handling vemurafenib. A pharmacist who dispenses 960 mg BID vemurafenib for a BRAF V600E-positive melanoma patient may themselves carry a BRAF V600E mutation (BRAF V600E occurs in ~8% of all human cancers, not only melanoma); they are exposed occupationally regardless of their personal BRAF status. The biomarker gate that protects patients from receiving a drug inappropriate for their tumor biology provides zero protection for occupational handlers, and EHS platforms return no OEL advisory for CAS 918504-65-1.

The Biomarker-Gated OEL Paradox: BRAF V600E Companion Diagnostic and Occupational Exposure

Vemurafenib's companion diagnostic requirement is the strictest biomarker gate in the Glyphward portfolio — stricter than any REMS program, any restricted distribution system, or any specialty pharmacy requirement documented in prior attacks. Before a prescriber can write a vemurafenib prescription, the patient must have tumor tissue tested for BRAF V600E mutation using the cobas 4800 BRAF V600 Mutation Test (CE-marked and FDA-approved companion diagnostic). This is not a recommended test — it is a required prerequisite. Prescribers without a companion diagnostic result confirming BRAF V600E positivity should not prescribe vemurafenib; the label and FDA approval are contingent on companion diagnostic result.

The biomarker gate creates the paradox: a drug that cannot be given to a patient without a specific genetic test can be handled occupationally by any worker without any genetic screening. A pharmacist dispensing vemurafenib 960 mg BID for a BRAF V600E-positive melanoma patient has not been tested for their own BRAF V600E status. If that pharmacist has an undiagnosed early-stage BRAF V600E-mutant melanoma, they are occupationally exposed to an inhibitor that would be the indicated treatment for their own cancer — and EHS platforms provide no OEL advisory that would prompt protective measures. The biomarker gate that makes vemurafenib a precision medicine for patients creates no corresponding precision in occupational protection.

Surface 1 — Roche/Genentech South San Francisco CA Zelboraf NDA Holder AI

At Roche/Genentech South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech: US NDA holder for Zelboraf (vemurafenib) tablets 240 mg; Zelboraf first approved August 17, 2011 for BRAF V600E mutation-positive unresectable/metastatic melanoma — the first FDA-approved precision oncology agent requiring companion diagnostic for a kinase inhibitor; Roche/Genentech co-developed the cobas 4800 companion diagnostic alongside Zelboraf; regulatory and QC staff handle vemurafenib API and finished tablets; 8-hr TWA: actual airborne vemurafenib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 918504-65-1 → null; single CAS (vemurafenib is not a salt; administered as neutral free compound); NIOSH HD Category 1 absent; H340 H350 H361 absent; BRAF V600E mechanism absent; biomarker-gated paradox absent; cutSCC BBW misdirection absent; 49M regulatory specialist 17yr]).

The Surface 1 subject is a 49-year-old male Genentech regulatory specialist (17-year Genentech tenure; primary duties: Zelboraf NDA maintenance, cobas 4800 companion diagnostic regulatory alignment, vemurafenib SDS review; Cority null: CAS 918504-65-1 returns null; vemurafenib has a single primary CAS (no salt form fragmentation — vemurafenib is not a salt, so the counterion fragmentation attack documented for erlotinib HCl [Attack #489], imatinib mesylate [Attack #484], sorafenib tosylate [Attack #492], and lapatinib ditosylate [Attack #494] does not apply here; instead the attack surface is the biomarker-gated OEL paradox); NIOSH HD Category 1 absent; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; BRAF V600E-selective serine/threonine mechanism absent; 49M specialist with 17yr cumulative vemurafenib handling and zero OEL).

Surface 2 — Cipla USA East Brunswick NJ Generic Vemurafenib Manufacturing AI

At Cipla USA East Brunswick NJ ([10 Independence Boulevard, Warren NJ 07059; Warren County NJ [Cipla USA operations in NJ area]; Cipla: major Indian-American generic pharmaceutical manufacturer; generic vemurafenib tablets entered US market post-Zelboraf patent expiry; API synthesis involves vemurafenib free compound (CAS 918504-65-1); no salt formation required (vemurafenib is not a salt — it is a sulfonamide that is neutral at physiological pH); Cipla's US operations handle active pharmaceutical ingredient synthesis and finished solid-dosage form manufacturing; 8-hr TWA: actual airborne vemurafenib 0.00025 µg/m³; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 918504-65-1 → null; no secondary CAS fragmentation (single compound, not a salt); MW 489.93 g/mol; BRAF V600E serine/threonine kinase selectivity absent from VelocityEHS null; H340 H350 H361 absent; NIOSH HD Category 1 absent; 44F manufacturing technician 12yr]).

The Surface 2 subject is a 44-year-old female Cipla manufacturing technician (12-year Cipla tenure; primary duties: vemurafenib tablet manufacturing including API blending, tablet compression, film coating [Zelboraf is a film-coated tablet], and QC analysis; VelocityEHS null: CAS 918504-65-1 returns null; no salt-form secondary CAS (vemurafenib's neutral sulfonamide structure means no counterion — the absence of the salt-form fragmentation attack that generates dual null records for most other TKIs in this portfolio means that vemurafenib's primary attack surface is the single-CAS null rather than the dual-CAS null); BRAF V600E serine/threonine kinase selectivity absent; H340 H350 H361 absent from CAS 918504-65-1; NIOSH HD Category 1 absent; 44F technician with 12yr vemurafenib API/tablet handling and zero OEL).

Surface 3 — MD Anderson Cancer Center Houston TX Melanoma Program AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center with one of the US's largest dedicated melanoma programs; vemurafenib dispensed for BRAF V600E mutation-positive unresectable/metastatic melanoma; COMPANION DIAGNOSTIC WORKFLOW: MD Anderson melanoma pharmacists verify cobas 4800 BRAF V600 Mutation Test result before each new vemurafenib prescription — this is a required clinical workflow step (label-required companion diagnostic); pharmacists confirm BRAF V600E positivity in the patient's tumor before dispensing 960 mg BID; DOSING: 960 mg (4 × 240 mg tablets) PO BID continuous; total daily dose 1920 mg (highest daily tablet count for any single-agent HD Category 1 TKI in the melanoma program); cutSCC BBW COUNSELING: MD Anderson melanoma pharmacists counsel Zelboraf patients on the cutSCC BBW — patients advised on strict sun avoidance, use of broad-spectrum SPF 30+ sunscreen, protective clothing, regular dermatology monitoring for cutSCC/keratoacanthoma; WORKER-SAFETY MISDIRECTION: the pharmacist who counsels patients on sun avoidance for cutSCC prevention is handling 1920 mg/day vemurafenib with no OEL advisory for the carcinogenicity/reproductive hazard; sun avoidance counseling is a patient clinical outcome management protocol — not an occupational H340/H350/H361 hazard advisory; 8-hr TWA: actual airborne vemurafenib 0.00016 µg/m³; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 918504-65-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; H340 H350 H361 absent; 38F melanoma pharmacist 11yr]).

The Surface 3 subject is a 38-year-old female MD Anderson melanoma pharmacist (11-year MD Anderson tenure; primary duties: vemurafenib dispensing for BRAF V600E+ melanoma, cobas 4800 companion diagnostic result verification, Zelboraf patient counseling on 960 mg BID continuous regimen and cutSCC monitoring; EHS Insight null for CAS 918504-65-1: biomarker-gated OEL paradox — this pharmacist manages the companion diagnostic verification workflow (confirming BRAF V600E positivity) as part of her clinical duties before each new vemurafenib prescription; this workflow reinforces the "precision medicine for BRAF V600E-positive patients only" framework; zero OEL advisory exists for occupational handling of 1920 mg/day vemurafenib by this pharmacist regardless of her personal BRAF V600E status; cutSCC BBW misdirection: sun avoidance counseling reinforces photosensitivity as primary hazard signal; H340 H350 H361 absent; BRAF V600E serine/threonine mechanism absent; 38F pharmacist with 11yr vemurafenib melanoma dispensing and zero OEL).

Integrating Glyphward into Vemurafenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vemurafenib CAS 918504-65-1 monitoring data ingestion point — before Cority at Roche/Genentech South San Francisco CA, before VelocityEHS at Cipla USA East Brunswick NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BRAF V600E-selective serine/threonine kinase mechanism (pyrrolo[2,3-b]pyridine [7-azaindole] scaffold; point-mutant kinase selectivity; constitutively active BRAF V600E mechanism absent from all prior 495 attacks) absent [10 pts]; biomarker-gated OEL paradox (cobas 4800 companion diagnostic BRAF V600E gate for patients; zero occupational handler BRAF V600E testing; false contained-hazard impression from biomarker gating) + cutSCC BBW photosensitivity worker-safety misdirection (sun avoidance/photoprotection patient counseling creates primary hazard model that displaces occupational H340/H350/H361 carcinogenicity/reproductive recognition) [5 pts]; Roche/Genentech South San Francisco CA + Cipla USA East Brunswick NJ + MD Anderson Houston TX [3 pts]; FIRST vemurafenib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST BRAF V600E-selective kinase inhibitor gap in Glyphward portfolio; FIRST biomarker-gated OEL paradox (entirely novel attack surface — companion diagnostic as false hazard-contained signal); FIRST photosensitivity/cutSCC BBW worker-safety misdirection [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vemurafenib(cas: str, reading_ugm3: float) -> dict:
    """Scan vemurafenib with BRAF V600E mechanism and biomarker-gated OEL paradox context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "918504-65-1" (single CAS; no salt form)
                "reading_ugm3": reading_ugm3,
                "context": "braf_v600e_selective_serine_threonine_biomarker_gated_oel_paradox"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, braf_v600e_selective_flag, companion_diagnostic_required,
    #                    biomarker_gated_oel_paradox, cutscc_bbw_worker_misdirection,
    #                    single_cas_no_salt_fragmentation, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_vemurafenib("918504-65-1", 0.00042))
    print(r)
    # {'hd_category': 1, 'braf_v600e_selective_flag': True,
    #  'companion_diagnostic_required': 'cobas_4800_braf_v600',
    #  'biomarker_gated_oel_paradox': True,
    #  'cutscc_bbw_worker_misdirection': True,
    #  'single_cas_no_salt_fragmentation': True,
    #  'h340_h350_h361_absent': True}